Primary tumor resection improves survival benefit of stage IVB cervical carcinoma: a new perspective

被引:5
作者
He, Yunan [1 ,2 ]
Zhang, Yishan [3 ]
Hu, Shunjie [4 ,5 ]
Zhang, Bolun [6 ,7 ]
Zhang, Zixu [8 ]
Yao, Yuanqing [6 ,7 ]
Wang, Xiaohong [1 ,2 ,9 ]
机构
[1] Air Force Med Univ, Tangdu Hosp, Dept Gynecol & Obstet, Xian, Shaanxi, Peoples R China
[2] Clin Res Ctr Reprod Med & Gynecol Endocrine Dis Sh, Xian, Shaanxi, Peoples R China
[3] Capital Med Univ, Beijing Tongren Hosp, Dept Urol, Beijing, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat, Shanghai, Peoples R China
[5] Fudan Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Shanghai, Peoples R China
[6] Nankai Univ, Sch Med, Tianjin, Peoples R China
[7] Univ Hong Kong, Shenzhen Hosp, Ctr Reprod Med, Shenzhen Key Lab Fertil Regulat, Shenzhen, Guangdong, Peoples R China
[8] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China
[9] Air Force Med Univ, Tangdu Hosp, Clin Res Ctr Reprod Med & Gynecol Endocrine Dis Sh, Dept Gynecol & Obstet, 1 Xinsi Rd, Xian, Shaanxi, Peoples R China
关键词
Primary tumor; Resection; Cervical carcinoma; Metastasis; Survival benefit; Prognosis; PROGNOSTIC-FACTORS; CANCER; BEVACIZUMAB; SURGERY;
D O I
10.1007/s00432-023-04988-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeRecent studies have revealed that primary tumor resection (PTR) surgery could improve prognosis in some solid tumors. Thus, we aimed to investigate whether patients with stage IVB cervical carcinoma can benefit from PTR surgery and who can benefit.MethodsWe extracted and obtained data on patients with stage IVB cervical carcinoma from the SEER database from 2010 to 2017 and classified them into two groups: the surgery and the non-surgery group. The overall survival (OS) and cancer-specific survival (CSS) of the two groups were compared before and after propensity score matching (PSM). The independent prognostic variables were identified using univariate and multivariate Cox regression analyses. Then, the model was established to select the optimal patients to receive PTR surgery using multivariate logistic regression.ResultsAfter PSM, the study included 476 cervical carcinoma (stage IVB) patients, of whom 238 underwent PTR surgery. Compared to the non-surgery group, the surgery group's median OS and median CSS were both longer (median OS: 27 months vs. 13 months, P < 0.001; median CSS: 52 months vs. 21 months, P < 0.001). The model showed no organ metastasis, adenocarcinoma, G1/2, and chemotherapy were more supportive of performing PTR surgery. The calibration curves and DCA showed that the model had high predictive accuracy and excellent clinical applicability. Finally, the "surgery benefit" group had the OS that was approximately four times better than "surgery non-benefit" group.ConclusionPTR surgery can potentially improve the prognosis of patients with cervical carcinoma at stage IVB. The model could probably select optimal candidates and provide a new perspective on individualized treatment.
引用
收藏
页码:11013 / 11023
页数:11
相关论文
共 22 条
[1]  
Tewari Krishnansu S, 2014, N Engl J Med, V370, P734, DOI [10.1056/NEJMx170002, 10.1056/NEJMoa1309748]
[2]  
Gyawali B, 2017, J GLOB ONCOL, V3, P93, DOI 10.1200/JGO.2016.004895
[3]   Cadonilimab: First Approval [J].
Keam, Susan J. .
DRUGS, 2022, 82 (12) :1333-1339
[4]   Curative Chemoradiotherapy in Patients With Stage IVB Cervical Cancer Presenting With Paraortic and Left Supraclavicular Lymph Node Metastases [J].
Kim, Ji-Yoon ;
Kim, Joo-Young ;
Kim, Jin Hee ;
Yoon, Mee Sun ;
Kim, Juree ;
Kim, Young Seok .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03) :741-747
[5]   Cervical Cancer, Version 3.2019 [J].
Koh, Wui-Jin ;
Abu-Rustum, Nadeem R. ;
Bean, Sarah ;
Bradley, Kristin ;
Campos, Susana M. ;
Cho, Kathleen R. ;
Chon, Hye Sook ;
Chu, Christina ;
Clark, Rachel ;
Cohn, David ;
Crispens, Marta Ann ;
Damast, Shari ;
Dorigo, Oliver ;
Eifel, Patricia J. ;
Fisher, Christine M. ;
Frederick, Peter ;
Gaffney, David K. ;
Han, Ernest ;
Huh, Warner K. ;
Lurain, John R., III ;
Mariani, Andrea ;
Mutch, David ;
Nagel, Christa ;
Nekhlyudov, Larissa ;
Fader, Amanda Nickles ;
Remmenga, Steven W. ;
Reynolds, R. Kevin ;
Tillmanns, Todd ;
Ueda, Stefanie ;
Wyse, Emily ;
Yashar, Catheryn M. ;
McMillian, Nicole R. ;
Scavone, Jillian L. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (01) :64-84
[6]   Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study [J].
Kuo, Shuenn-Wen ;
Chen, Pei-Hsing ;
Lu, Tzu-Pin ;
Chen, Ke-Cheng ;
Liao, Hsien-Chi ;
Tsou, Kuan-Chuan ;
Tsai, Tung-Ming ;
Lin, Mong-Wei ;
Hsu, Hsao-Hsun ;
Chen, Jin-Shing .
ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (08) :4873-4884
[7]   Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy [J].
Kwon, ED ;
Foster, BA ;
Hurwitz, AA ;
Madias, C ;
Allison, JP ;
Greenberg, NM ;
Burg, MB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15074-15079
[8]   Stage IIB-IVB cervical adenocarcinoma: Prognostic factors and survival [J].
Lea, JS ;
Sheets, EE ;
Wenham, RM ;
Duska, LR ;
Coleman, RL ;
Miller, DS ;
Schorge, JO .
GYNECOLOGIC ONCOLOGY, 2002, 84 (01) :115-119
[9]   Surgery of primary sites for stage IVB cervical cancer patients receiving chemoradiotherapy: a population-based study [J].
Li, Haoran ;
Pang, Yangyang ;
Cheng, Xi .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (01)
[10]   Advances in diagnosis and treatment of metastatic cervical cancer [J].
Li, Haoran ;
Wu, Xiaohua ;
Cheng, Xi .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2016, 27 (04)